Cadila Healthcare announced that the Company's formulations manufacturing facility located at Baddi, India has received an Establishment Inspection Report (EIR). The EIR report stated that the
classification of the facility is 'No Action Indicated (NAI)'. The USFDA had conducted an inspection at the facility from 2nd to 9th March, 2020. The audit had ended with nil observations.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
